Form 424B5 Bionano Genomics, Inc
EDGARFILINGS LTD, 07 January 2021
Common Stock We are offering shares of our common stock at a purchase price of $ per share pursuant to this prospectus supplement. Our common stock is listed on the Nasdaq Capital Market under the symbol “BNGO.” On January 6, 2021, the last reported sale price of our common stock was $4.77 per share. We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus supplement and may elect to do so in future filings. Our business and an investment in our securities involve significant risks. These risks are described under the caption “Risk Factors” beginning on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
Read Full Article
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Yahoo Finance, 06 January 2021
Daix (France), January 5, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH following the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) and the receipt of the Scientific Advice letter from the European Medicines Agency (EMA). The Phase III trial design and clinical strategy have been discussed with both regulatory authorities and the following key points can be confirmed:
Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on a 72-week histology analysis – Inventiva will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients after 72 weeks establishing a positive benefit-risk ratio.
Read Full Article
Americas Gold and Silver Corporation Provides an Update on the Galena Complex and Relief Canyon Mine
BUSINESS WIRE, 06 January 2021
Americas Gold and Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas”, “Americas Gold and Silver” or the “Company”), a growing North American precious metals producer, is pleased to provide an update on the Galena Complex and the Relief Canyon mine.
“The Galena Complex is demonstrating the positive impact of having a diversified portfolio of assets and commodities,” stated Americas Gold and Silver President & CEO Darren Blasutti. “While I am disappointed by the unexpected delay in declaring commercial production at Relief Canyon, the health and safety of our workers far outweighs pushing to declare commercial production. We are having a strong start to 2021 at Relief Canyon, our key employees have returned to the site and the stacker is operating well. We look forward to declaring commercial production at Relief Canyon shortly.”
Continue reading “Article: Americas Gold and Silver Corporation Provides an Update on the Galena Complex and Relief Canyon Mine”
Joseph Hooley Net Worth
Wallmine, 06 January 2021
The estimated Net Worth of Joseph L Hooley is at least $63.1 Million dollars as of 31 October 2019. Joseph Hooley owns over 25,000 units of Exxon Mobil stock worth over $40,764,066 and over the last 7 years he sold XOM stock worth over $22,314,161. In addition, he makes $0 as Director at Exxon Mobil. Continue reading “Article: Joseph Hooley Net Worth”
PATRICK BYRNE GIVE REAL HOPE IN ELECTION FRAUD INVESTIGATION
Cooter, 05 January 2021
We’ve learned some new and very important information thanks to former Overstock CEO Patrick Byrne this week. They’ve now been able to confirm and corroborate the testimony and sworn affidavit of the USPS worker who said that he drove ballots from New York to Pennsylvania. Continue reading “Article: PATRICK BYRNE GIVE REAL HOPE IN ELECTION FRAUD INVESTIGATION”
In GameStop saga, U.S. regulator examining all aspects and parties: sources
Chris Prentice, Pete Schroeder, 05 January 2021
WASHINGTON (Reuters) – The U.S. Securities and Exchange Commission (SEC) is looking at every aspect of and parties involved in the “Reddit rally” of GameStop Corp and other stocks, said two people familiar with the matter, suggesting a swath of industry participants may be swept up in the regulator’s review of the trading frenzy.
The people added that the furious surge in shares of GameStop, AMC Entertainment Holdings and other stocks contained familiar patterns, in that it involves users of online platforms hyping up stocks – something seen in the past on bulletin boards and social media platforms.
However, manipulation cases can be complex and may rely on more than simply language posted on a message board, they said.
Read Full Article
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of OrthoPediatrics Corp. (KIDS) on Behalf of Investors
BUSINESS WIRE, 05 January 2021
On December 2, 2020, Culper Research issued a report entitled “OrthoPediatrics Corp. (KIDS): Even Channel Stuffing Can’t Save This Company,” alleging that the Company “engaged in a channel stuffing scheme that has systematically and significantly overstated revenues.” Citing interviews with distributors and former executives, the report alleged that “distributors have been induced to buy excess product directly from the Company in exchange for (a) equity-based awards, (b) the opportunity to return product, and/or (c) product discounts or increased commission schedules.” On this news, the Company’s stock price fell $4.12 per share, or 9%, to close at $41.02 per share on December 2, 2020, thereby injuring investors.
Continue reading “Article: Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of OrthoPediatrics Corp. (KIDS) on Behalf of Investors”
NAK Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against Northern Dynasty Minerals Ltd. (NYSE: NAK); Lead Plaintiff Deadline is February 2, 2021
PRNewswire, 05 January 2021
Berger Montague is investigating potential securities fraud claims against Northern Dynasty Minerals Ltd. (“Northern Dynasty” or the “Company”) on behalf of investors who purchased Northern Dynasty securities (NYSE: NAK) between December 21, 2017 and November 25, 2020 (the “Class Period”).
A recently filed lawsuit accuses Northern Dynasty and its senior management of misleading investors about the Company’s proposed Pebble Project, a large mining project in Alaska, and its prospects for securing a permit from federal and state regulators. Northern Dynasty repeatedly touted its progress in obtaining the necessary permits for the Pebble Project and assured investors that its design entailed a substantially reduced development footprint and new environmental safeguards for the mine.
Continue reading “Article: NAK Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against Northern Dynasty Minerals Ltd. (NYSE: NAK); Lead Plaintiff Deadline is February 2, 2021”
Steve Cohen Rides Point72 Gains to $1.4 Billion in Personal Earnings
Stephen Taub, 05 January 2021
Steven Cohen’s Point72 Asset Management just posted its best year since it launched with outside money in 2018 — capping what has been a remarkable professional and personal comeback for the founder of now-defunct SAC Capital Advisors. Continue reading “Article: Steve Cohen Rides Point72 Gains to $1.4 Billion in Personal Earnings”
MEMORANDUM FOR THE PRESIDENT OF THE UNITED STATES OF AMERICA
Subject: Immediate Opportunity to Confiscate $100 Trillion from Wall Street
29 December 2020
Continue reading “Memorandum for the President #6: $100 Trillion in Illicit Wealth Immediately Confiscatable from Wall Street”
Penumbra, Inc. Investors: Company Investigated by the Portnoy Law Firm
GLOBE NEWSWIRE, 04 January 2021
The Portnoy Law Firm advises Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE: PEN) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: firstname.lastname@example.org, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On November 10, 2020, released research report on Penumbra was released by Quintessential Capital Management entitled “Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]”
Continue reading “Article: Penumbra, Inc. Investors: Company Investigated by the Portnoy Law Firm”
Exuberance Over Good News Drives Bionano Genomics’ Wild Week
John Alford, 04 January 2021
Bionano Genomics, Inc. (BNGO) has been on a wild, meteoric rise in the past few days, and after hours on the 31st it continued to skyrocket, rising to $4 a share. On the 31st of December alone, counting market and after-hours trading, share prices surged $1.90, almost doubling. This capped a wild week, and is a momentum-driven mania trade not based on the previous performance or long-term trend of the company. While recently reporting one good report (via a paid PR service), there are obvious issues surrounding the company to the investor that takes the time to evaluate their most recent 10-Q, recent and potential massive dilution, and decreasing revenue. Continue reading “Article: Exuberance Over Good News Drives Bionano Genomics’ Wild Week”